Lipid Nanoparticle– tag –
-
Tuning siRNA Packing Order in Lipid Nanoparticles Controls Oligonucleotide Functional Delivery
bioRxiv (Preprint) International Overview This preprint investigates how tuning the siRNA packing order within lipid nanoparticles (LNPs) can modulate oligonucleotide functional delivery, addressing a key challenge in RNA therapeutics: e... -
Wave Life Sciences Reports Positive RNA Editing Clinical Data for WVE-006 in Alpha-1 Antitrypsin Deficiency (AATD)
BioPharm International USA Overview Wave Life Sciences announced favorable clinical data from the RestorAATion-2 trial of WVE-006, an RNA editing therapeutic for Alpha-1 Antitrypsin Deficiency (AATD). WVE-006, a GalNAc-conjugated RNA edi... -
Eli Lilly Acquires Engage Biologics for Up to $202 Million to Strengthen Non-Viral DNA Delivery Platform
GuruFocus USA Overview Eli Lilly has agreed to acquire Engage Biologics for up to $202 million, aiming to leverage Engage’s innovative non-viral DNA delivery platform and accelerate the development of next-generation gene therapies. Enga... -
Translational Progress in Lipid Nanoparticle Drug Delivery Systems for Cancer Therapy: Current Status and Future Horizons
PMC (PubMed Central) International Overview This review article comprehensively examines lipid nanoparticles (LNPs) as highly adaptable nanocarrier systems for cancer therapy and diagnostics. LNPs leverage structural flexibility, biocomp... -
SelectBIO to Host Lipid Nanoparticles (LNPs) Asia/Pacific 2026: Driving mRNA Delivery Innovations
SelectBIO Conferences UK Overview SelectBIO Conferences will host the 'Lipid Nanoparticles (LNPs) Asia/Pacific 2026' event, focusing on LNPs, extracellular vesicles, exosomes, and Japanese research. The conference will primarily address ... -
Advanced Lipid Nanoparticles Revolutionize Nucleic Acid and Gene-Editing Therapeutic Delivery
PMC (PubMed Central) USA Overview Lipid nanoparticles (LNPs) are becoming indispensable for efficient intracellular delivery of nucleic acid, mRNA, and gene-editing therapeutics, shielding them from degradation in circulation. Proven eff... -
The In Vivo CAR-T Race Heats Up: Big Pharma Acquisitions and Astellas’ Strategic Collaborations Signal a New Era in Cancer Therapy
Answers（アンサーズ） Japan Overview The global race to develop 'in vivo CAR-T therapy,' which generates CAR-T cells directly within the patient's body, is intensely accelerating as major pharmaceutical companies invest heavily. This inn...
